13th Jul 2015 08:54
LONDON (Alliance News) - Biofrontera AG on Monday said it has submitted a new drug application to the US Food and Drug Administration for its combination prescription drug Ameluz and its BF-RhodoLED medical device.
The combination of the two products will be used in photodynamic therapy in the US market, should the application be approved.
"A New Drug Application in the US, in particular a combination drug/medical device submission, is a huge endeavour and it involves every single employee in our small company," said Biofrontera Chief Executive Hermann Lübbert.
Biofrontera shares were untraded Monday at 175.30 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L